Evidence map›Paper›PMID 39845638›Full record

ArticleSurgery in practice and science2024

Receptor discordance after nipple-sparing mastectomy.

Rena Kojima, Makoto Ishitobi, Naomi Nagura, Ayaka Shimo, Hirohito Seki, Akiko Ogiya, Teruhisa Sakurai, Yukiko Seto, Shinsuke Sasada, Chiya Oshiro and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Surgery in practice and science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Rena KojimaDepartment of Breast Surgery, Mie University School of Medicine, Mie, Japan.
Makoto IshitobiDepartment of Breast Surgery, Mie University School of Medicine, Mie, Japan.
Naomi NaguraDepartment of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan.
Ayaka ShimoDepartment of Breast and Endocrine Surgery, St. Marianna University School of Medicine, Kanagawa, Japan.
Hirohito SekiDepartment of Breast Surgery, Saitama Medical Center, Saitama, Japan.
Akiko OgiyaDepartment of Breast Surgical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Teruhisa SakuraiSakurai Breast Clinic, Wakayama, Japan.
Yukiko SetoDepartment of Breast and Endocrine Surgery, Osaka International Cancer Institute, Osaka, Japan.
Shinsuke SasadaDepartment of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
Chiya OshiroDepartment of Breast Surgery, Kaizuka City Hospital, Osaka, Japan.
Michiko KatoDepartment of Breast Surgical Oncology, Showa University School of Medicine, Tokyo, Japan.
Takahiko KawateDepartment of Breast Surgery and Oncology, Tokyo Medical University Hospital, Tokyo, Japan.
Naoto KondoDepartment of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Tadahiko ShienDepartment of Breast and Endocrine Surgery, Okayama University Hospital, Okayama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Recent studies have shown that receptor status of breast cancer change between primary tumor and recurrence, which may influence treatment strategy and prognosis, but there are few reports on receptor discordance between primary tumors and local recurrence (LR) after nipple-sparing mastectomy (NSM). Patients and methods: We collected 74 patients who had LR after NSM for newly diagnosed stages 0 to 3 breast cancer between 2008 and 2016 at 14 institutions. We classified into 4 subtypes based on hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2). We evaluated clinicopathological factors that correlate with receptor discordance and assessed the impact of receptor discordance on survival. Results: Discordance rates in estrogen receptor (ER), progesterone receptor (PgR) and HER2 were 9.5, 10.8 and 5.4 %, respectively. The most common change was from HR-/HER2+ to HR+/HER2+, and this pattern of receptor change occurred only in patients with nipple-areolar recurrence. Non-invasive tumors in LR, nipple-areolar recurrence (NAR), HR-/HER2+ primary tumor subtype, and the presence of chemotherapy for primary tumors were significantly associated with receptor discordance. With a median follow-up of 44.5 months (4-153 months), patients in the receptor-discordant group had no disease-free survival (DFS) event after LR resection (5-year DFS; 100 % in the receptor-discordant group vs 85.1 % in the receptor-concordant group; Conclusion: Our study demonstrates that the presence of chemotherapy for primary tumors, nipple-areolar recurrence, and its related factors (non-invasive tumor in LR, HR-/HER2+ primary tumor subtype) were associated with receptor discordance. However, further studies with longer follow-up periods and larger sample sizes are needed.

Indexed as

Breast cancerLocal recurrenceNipple–areolar recurrenceNipple-sparing mastectomySubtype

Identifiers

PMID39845638
PMCPMC11749963

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.